Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors
- 1 August 2007
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 28 (8) , 407-415
- https://doi.org/10.1016/j.tips.2007.06.009
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Determining the Potency and Molecular Mechanism of Action of Insurmountable AntagonistsThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Distinct Signaling Profiles of β1 and β2 Adrenergic Receptor Ligands toward Adenylyl Cyclase and Mitogen-Activated Protein Kinase Reveals the Pluridimensionality of EfficacyMolecular Pharmacology, 2006
- Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progressionBlood, 2006
- New Concepts in Drug Discovery: Collateral Efficacy and Permissive AntagonismNature Reviews Drug Discovery, 2005
- Multiple Signaling States of G-Protein-Coupled ReceptorsPharmacological Reviews, 2005
- The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry InhibitorMolecular Pharmacology, 2005
- Activation-independent Parathyroid Hormone Receptor Internalization Is Regulated by NHERF1 (EBP50)Journal of Biological Chemistry, 2003
- β-Arrestin Scaffolding of the ERK Cascade Enhances Cytosolic ERK Activity but Inhibits ERK-mediated Transcription following Angiotensin AT1a Receptor StimulationJournal of Biological Chemistry, 2002
- Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2Adrenergic ReceptorJournal of Biological Chemistry, 2001
- Fluorescent Labeling of Purified β2 Adrenergic ReceptorPublished by Elsevier ,1995